Oncology Views & Analysis

Views & Analysis

Oncology

Can CAR-T first movers keep pace in a rapidly evolving marke...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.

Oncology

Abstract illustration of targeting cancer cell

How automating flow cytometry is revolutionising cancer diag...

As the incidence of cancer rises around the world, the demand for faster, more precise diagnoses is also on the rise.

Oncology

Driving innovation in multiple myeloma to improve the patien...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.1

Oncology

CAR-T therapies: Faster, better, cheaper

In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.

Oncology

Inside ESMO 2024: Treatments, trials, and top HCPs on social...

Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.

Oncology

12 Questions with Gerhard du Toit

As Global Head of Oncology for IQVIA Biotech, Gerhard du Toit manages all aspects of oncology clinical trials, optimising strategies and enhancing delivery from early to late phases.

Can CAR-T first movers keep pace in a rapidly evolving marke...

How automating flow cytometry is revolutionising cancer diag...

Driving innovation in multiple myeloma to improve the patien...

CAR-T therapies: Faster, better, cheaper

Inside ESMO 2024: Treatments, trials, and top HCPs on social...

12 Questions with Gerhard du Toit

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks